EMERYVILLE, Calif.,
March 2, 2011 /PRNewswire/ -- Onyx
Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will
present at the Cowen and Company 31st Annual Health Care Conference
on Wednesday, March 9, 2011 at
11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
Interested parties may access a live webcast of the presentation
on our website at:
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar
It is recommended that listeners log on 15 minutes early in
order to register and download any necessary software. For
those unable to participate during the live webcast, a recorded
replay of the presentation will be available within 24 hours of the
completion of the presentation through March
23, 2011.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company
committed to improving the lives of people with cancer. The
company, in collaboration with Bayer HealthCare Pharmaceuticals
Inc., is developing and marketing Nexavar® (sorafenib) tablets, a
small molecule drug that is currently approved for the treatment of
liver cancer and advanced kidney cancer. Additionally, Nexavar is
being investigated in several ongoing trials in a variety of tumor
types. Beyond Nexavar, Onyx has established a development pipeline
of anticancer compounds at various stages of clinical testing,
including carfilzomib, a selective proteasome inhibitor, that is
currently being evaluated in multiple clinical trials for the
treatment of patients with relapsed or relapsed/refractory multiple
myeloma and solid tumors. ONX 0801, an alpha-folate receptor
targeted inhibitor of thymidylate synthase, and ONX 0912, an oral
proteasome inhibitor, are currently in Phase 1 testing. For more
information about Onyx, visit the company's website at
www.onyx-pharm.com.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer
HealthCare Pharmaceuticals.
SOURCE Onyx Pharmaceuticals, Inc.